PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.

Abstract The proteasome beta-4 subunit is required for the assembly of 20S proteasome complex, forming a pivotal component for the ubiquitin-proteasome system. Emerging evidence indicates that proteasome beta-4 subunit may be involved in underlying progression and mechanisms of malignancies. However, the role of proteasome beta-4 subunit in melanoma is currently unknown. Here, we reported that proteasome beta-4 subunit was markedly upregulated in human melanoma tissues and cells, compared with normal skin samples. High proteasome beta-4 subunit levels were significantly associated with poor overall survival in patients with melanoma. Proteasome beta-4 subunit knockdown strongly decreased melanoma cell growth in vitro and in vivo. We further identified miR-148b as a negative regulator of proteasome beta-4 subunit. Enforced expression of miR-148b resulted in vitro growth inhibition of melanoma cells, whereas this inhibition was further abolished by enforced expression of proteasome beta-4 subunit. Our findings, for the first time, indicated that the miR-148b/proteasome beta-4 subunit axis contributed to the development of melanoma, revealing novel therapeutic targets for the treatment of melanoma.
PMID
Related Publications

Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.

MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway.

Upregulated MicroRNA-25 Mediates the Migration of Melanoma Cells by Targeting DKK3 through the WNT/β-Catenin Pathway.

PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer.

IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.

Authors

Mayor MeshTerms
Keywords

Proteasome beta-4 subunit

melanoma

miR-148b

targeted therapy

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28656878
OWN - NLM
STAT- MEDLINE
DA  - 20170628
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Proteasome beta-4 subunit contributes to the development of melanoma and is
      regulated by miR-148b.
PG  - 1010428317705767
LID - 10.1177/1010428317705767 [doi]
AB  - The proteasome beta-4 subunit is required for the assembly of 20S proteasome
      complex, forming a pivotal component for the ubiquitin-proteasome system.
      Emerging evidence indicates that proteasome beta-4 subunit may be involved in
      underlying progression and mechanisms of malignancies. However, the role of
      proteasome beta-4 subunit in melanoma is currently unknown. Here, we reported
      that proteasome beta-4 subunit was markedly upregulated in human melanoma tissues
      and cells, compared with normal skin samples. High proteasome beta-4 subunit
      levels were significantly associated with poor overall survival in patients with 
      melanoma. Proteasome beta-4 subunit knockdown strongly decreased melanoma cell
      growth in vitro and in vivo. We further identified miR-148b as a negative
      regulator of proteasome beta-4 subunit. Enforced expression of miR-148b resulted 
      in vitro growth inhibition of melanoma cells, whereas this inhibition was further
      abolished by enforced expression of proteasome beta-4 subunit. Our findings, for 
      the first time, indicated that the miR-148b/proteasome beta-4 subunit axis
      contributed to the development of melanoma, revealing novel therapeutic targets
      for the treatment of melanoma.
FAU - Zhang, Xiaodong
AU  - Zhang X
AD  - 1 Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases
      and STIs, Nanjing, China.
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Lin, Di
AU  - Lin D
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Lin, Yueqin
AU  - Lin Y
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Chen, Hongqing
AU  - Chen H
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Zou, Minghua
AU  - Zou M
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Zhong, Shan
AU  - Zhong S
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Yi, Xuefeng
AU  - Yi X
AD  - 2 Department of Dermatology, Guangdong Provincial Si'an Hospital, Dongguan,
      China.
FAU - Han, Siqi
AU  - Han S
AD  - 3 Department of Medical Oncology, Jinling Hospital, Nanjing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (MIRN148 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 3.4.22.- (PSMB4 protein, human)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinogenesis/*genetics
MH  - Cell Proliferation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Male
MH  - Melanoma/*genetics/pathology
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Proteasome Endopeptidase Complex/*genetics
OTO - NOTNLM
OT  - Proteasome beta-4 subunit
OT  - melanoma
OT  - miR-148b
OT  - targeted therapy
EDAT- 2017/06/29 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/29 06:00
AID - 10.1177/1010428317705767 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317705767. doi: 10.1177/1010428317705767.